Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said polysaccharide is selected from the group consisting of an outer-polysaccharide, a Polysaccharide B and a polysaccharide cross-reactive therewith, said polysaccharide containing a 1,2 β linked glucose.

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species , wherein said outer-polysaccharide comprises of a polymer of 4-formamido-4,6-dideoxy-D-mannose sugar.

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said Polysaccharide B comprises of a polymer of circular 1,2 β linked glucose.

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide which contains a circular 1,2 β linked glucose, and has been isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said outer-polysaccharide is extracted from said second bacterial species selected from the group consisting of Brucella abortus, Brucella suis, Brucella melitensis, Brucella neotomae, Yersinia enterocolitica O:9 Francisella tularensis, Vibrio cholerae, Pseudomonas maltophilia 555, Escherichia coli O:15-H:7, Escherichia hermanii, Salmonella landau, Salmonella gosdesberg and a cross reactant thereof.

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide which contains a circular 1,2 β linked glucose, and has been isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said Polysaccharide B is extracted from said second bacterial species selected from the group consisting of Brucella abortus, Brucella melitensis and Agrobacterium tumefaciens.

The method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated naturally soluble polysaccharide which contains a circular 1,2 β linked glucose, and has been isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said first bacterial species is selected from the group consisting of Brucella and Haemophilus pleurnpneumoniae.

A method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering intravenously a vaccine comprising a naturally soluble polysaccharide isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, wherein said polysaccharide is selected from the group consisting of an outer-polysaccharide, a Polysaccharide B and a polysaccharide cross-reactive therewith, said polysaccharide containing a circular 1,2 β linked glucose.

A method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering an immunomodulator comprising a non-phosphorylated polysaccharide isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, and said polysaccharide is characterized by being soluble in water.

A method of treating a mammal against an infection caused by a first bacterial species, said method comprising administering intravenously a vaccine comprising a polysaccharide which contains a circular 1,2 β linked glucose, and has been isolated from a second bacterial species to enhance phagocytic activities of macrophages in said mammal, wherein said first bacterial species is from another species than said second bacterial species, and said polysaccharide is characterized by being soluble in water.